Physicians and patients have variable and individual levels of comfort regarding when to begin salvage therapy for rising prostate specific antigen (PSA) after definitive treatment of prostate cancer. The decision to start salvage therapy is a multifactorial process for which few rigorous data or guidelines exist. A questionnaire survey of urologists of the Department of Defense (DoD) Center for Prostate Disease Research (CPDR) was undertaken to obtain current perspectives on when to begin salvage therapy for biochemical failure after definitive therapy. Variables of age, grade, T-stage, nodal status, performance status, latency since prior therapy, PSA velocity, and ploidy were prioritized in four clinical situations; subsequent questions assessed consensus PSA cut-offs for beginning adjuvant therapy in 84 clinical scenarios. Consensus on PSA cut-off points was limited to postoperative radiotherapy (RT), where values of 1.0 -1.5 were the mean cut-off points. CPDR urologists consider salvage prostatectomy post-RT only for patients < 70-y-old with node negative, grade 2 -7 disease and excellent performance status. Ploidy was not generally considered useful in any scenario. Many variables in addition to PSA level are involved in the decision of when to commence adjuvant therapy for initial biochemical failure. These are strikingly interdependent, and few clear absolutes are evident from this questionnaire. This is a point of necessary further research and continued discussion among physicians caring for these patients.
Introduction
The most frequent current clinical scenario in which clinicians encounter advanced prostate cancer is in the context of recurrent disease. Physicians and patients have individual levels of comfort regarding when to begin salvage therapy for rising prostate specific antigen (PSA) after definitive treatment of localized prostate cancer. This decision to start salvage therapy is a multifactorial process for which few guidelines exist. 1, 2 Physicians' decisions are based on data that may be unclear or inconclusive.
In the United States military, urologists are generally responsible for starting salvage therapy, since they for the most part manage hormonal therapy and make referrals for post-operative radiotherapy. Medical oncology does not have a robust role in the immediate salvage therapy of prostate cancer patients within the Department of Defense (DoD) military healthcare system, and radiation oncologists, while following patients post-radiotherapy (post-RT), generally do not manage hormonal therapy. Therefore, a survey was performed of DoD Center for Prostate Disease Research (CPDR) urologists to determine individual practices in treating PSA-only recurrence.
Methods
A survey questionnaire to CPDR urologists was undertaken in August 1998, to obtain a 'snapshot' of current perspectives on when they begin salvage therapy for biochemical failure after definitive therapy (Appendix 1). Surveys were addressed to the urology staff at the 10 DoD facilities with comprehensive cancer programs: Naval Medical Centers in San Diego, CA, Bethesda, MD, and Portsmouth, VA; Air Force Medical Centers in Biloxi, MS, Dayton, OH, and San Antonio, TX; and Army Medical Centers in Washington, D.C., San Antonio, TX, Tacoma, WA, and Honolulu, HI. In the first part of this survey, eight clinical variables (age, grade, T-stage, nodal status, performance status, latency since prior therapy, PSA velocity and ploidy) were prioritized from one (very important) to eight (unimportant) for a rising PSA in four clinical situations: radiotherapy (RT) after radical prostatectomy (RP), hormonal therapy after RP, RP after RT, and hormonal therapy after RT.
For each clinical situation, the 23 subject physicians ranked the eight clinical factors according to their views of relative importance. Thus, age, for example, could be ranked first (most important factor in making a clinical decision) from 0 to 23 times. The data compose an 8 6 8 table of ranking frequencies with the clinical factors along the side and the ranking positions first through to eighth along the top. For example, for post-operative RT, the top row showed the frequency of rankings 1 through to 8 for age as 4, 3, 2, 1, 0, 8, 2, 3. Thus, age was ranked first (most important clinical factor) by four rankers, second by three, etc.
The two questions addressed were: (1) What was the median ranking for each indicator, and (2) How well did the urologists agree on this average ranking? To answer the first question, medians of the 23 rankings were calculated. For the age frequencies noted above, the median was 6.
The second question was answered by calculating an agreement coefficient. The commonly used agreement or concordance coefficients, for example Cohen's kappa, were not designed for forced rankings among the same raters, do not weigh disparities between raters, and are designed for a small number of raters. For example, kappa for larger numbers of raters is calculated by an amalgam of sub-calculations in which each is category sequentially compared with all others combined. The interpretation of resulting kappa values is obscure and arbitrary. We designed a method in which per cent agreement was calculated simply and is easy to interpret.
To find a per cent agreement, a disagreement value was first calculated as the sum of frequencies weighted by the ranking distance from the median. For example, in the rank distribution for age shown above, the median is 6 (with eight rankers choosing that value). No one ranked it fifth, and two ranked it seventh (both of these are one rank away from the median of sixth). One ranked it fourth, and three ranked it eighth (two ranks away from the median of sixth). Thus, the disagreement (d) would be 5
We finally considered how any value would compare with a random ranking. The average (mathematical expectation) of random assignment would occur with the same frequency for each ranking, or 23/8 ¼ 2.875 with a median of 4.5. The per cent agreement calculates to 40.26%. In the example, while age is considered of median importance equal to 6, the 38% agreement is poor since it is less than the approximately 40% predicted by chance.
In the second part of the survey (Appendix 1B), PSA cutoffs for beginning salvage therapy were solicited in 84 clinical scenarios. These scenarios were generated by varying the levels of the above clinical factors (ages < 70 or 70; grades 2 -4, 5 -6, 7, or 8 -10; T-stages T2A, T2B, T3A, or T3B; node positive or negative; performance status normal, unable to work but able to care for self, or requiring institutional care; latency since prior therapy 1 y or > 1 y; 'low' or 'high' PSA velocity [exact values were not defined]; and an aneuploid or diploid lesion).
Results
Urologists at the major DoD facilities with comprehensive cancer programs were queried. Twenty-three questionnaires were returned. Median values with associated per cent concordance were calculated for the rank of each clinical variable in importance for initiating salvage therapy (Figures 1 -4 ). For these figures, median ranking is plotted in terms of per cent agreement. Thus, a highranking factor with high agreement will be plotted higher and more to the right. In general, grade, T-stage, and ploidy always had high per cent agreements (above 60%), but of varying importance. No single factor had consistent importance across the four clinical scenarios.
In the situation of salvage RT for a rising post-prostatectomy PSA, there was not one overall variable considered most important. Instead, three variables -T-stage, time since surgery, and PSA velocity -each had a median rank of 3, with agreements of 65, 51 and 45%, respectively.
PSA velocity was also one of the most important factors for starting hormonal therapy post-prostatectomy, with a median rank of 2 and agreement of 53%. Sharing this rank in this situation was nodal status, with an agreement of 52%.
PSA velocity and nodal status were also the most important when considering hormonal therapy after RT, ranked second (agreement of 61%) and third (agreement of 56%). Age also had a median rank of 3, but with agreement of only 38% (less than chance).
For salvage prostatectomy following RT, age had the highest median rank (2), with 71% agreement, followed by T-stage, which had a rank of 3 with 66% agreement.
In general, PSA velocity was the most important clinical variable, with a median rank of 2 or 3 for RT post-RP and hormonal therapy post-RP and post-RT. Ploidy was consistently felt to be unimportant, with a median rank of 8 and high agreement in all four clinical situations.
Mean values for the PSA cut-off at which to institute salvage therapy were calculated (Table 1) . Consensus was limited to postoperative RT, post-RT salvage prostatectomy, and treatment of patients with poor performance status.
For beginning salvage RT postoperatively, all mean PSA cut-offs fell between 1 and 2 except for patients aged 70, positive nodes, or poor performance status. Another area of reluctance involved post-RT salvage prostatectomy, where patient selection involving all clinical factors was important. This intervention was never recommended in many cases; for the remainder, PSA cut-offs were either between 4 and 5. Patient performance status, although never attaining a median rank more important than 4 among individual clinical factors prioritized for each situation, made a clear difference in PSA cut-off level. CPDR urologists consistently increased allowable PSA values or revised their recommendations to 'never' as function declined. An overwhelming majority never recommended salvage therapy besides hormones for patients requiring institutional care.
Discussion
This small study demonstrates the wide variability in patient care based largely on physician and patient preference. The lack of a unified approach to this frequentlyoccurring clinical situation is contributed to by a paucity of strong clinical data. The following sections review 
Postoperative radiotherapy
Consensus in the literature, as in this survey, is difficult to find. It is not even clear whether a rising post-prostatectomy PSA mandates any treatment. Jhaveri and colleagues demonstrated 10-y actuarial cause specific survival rates between post-RP patients with and without biochemical failure were not statistically different. 3 Pound and associates studied the outcome of post-prostatectomy patients with a PSA-only recurrence, finding that with observation alone, the median time until the development of metastases was 8 y and median time until death after developing metastases and beginning hormones was another 5 y. 4 There are currently no randomized trials addressing salvage RT post-RP for biochemical-only failure. The studies that are available are preliminary and retrospective, lacking long-term follow-up and therefore information on the overall impact on survival. 4 However, observational studies have demonstrated that 50 -70% of post-prostatectomy patients do not develop a local recurrence. 5 The American Society for Therapeutic Radiology and Oncology (ASTRO) Consensus Panel recognized these limitations in the literature, and was unable to conclude whether the PSA remission obtained by postprostatectomy RT is durable. 6 In light of a PSA response to RT, however, they, like the CPDR urologists, recommended 1.5 as the cut-off PSA level at which to start RT post-RP. Randomized trials will address the role and timing of postoperative RT in the future. Notably, this population is also a prime one for assessment of systemic therapies with chemotherapy.
Salvage prostatectomy post-radiotherapy
Salvage prostatectomy involves a treatment with considerable complications, including a 100% rate of impotence and 60% rate of incontinence, and has a high recurrence rate with no proven survival benefit. 7 For these reasons, patient selection is critical to maximize the likelihood the patient has a local recurrence only. It was only after the questionnaire was completed that a study by Amling and associates found DNA ploidy to be the strongest predictor of cancer specific survival and progression free survival in patients receiving RP post-RT; 8 this explains the discrepancy as to why ploidy was considered least important by the study participants. Other recommendations also include good general health, life expectancy greater than 10 y, pre-salvage PSA less than 10, and a patient who had potentially been curable by surgery prior to RT, who accepts the high risk of complications. 4, 8 All of these data are based on retrospective experiences, but a small pilot trial investigating salvage prostatectomy is underway under the auspices of Cancer and Leukemia Group B and the Southwest Oncology Group.
Hormonal therapy in general
Hormonal therapy for rising PSA after definitive therapy is widely termed 'salvage', although in honesty no such expectation exists. With the expectation of prolonged survival, there is virtually no realistic hope for cure given this modality. A more precise term may be 'secondary' hormonal therapy, although this has yet to achieve widespread use.
Hormonal therapy post-radiotherapy
A number of different hormonal regimens are available: gonadal ablation through bilateral orchiectomy or gonadotropin releasing hormone analogues, antiandrogens, or a combination of both. Medications can be used either continuously or intermittently. Intermittent therapy theoretically delays the almost inevitable progression to an androgen independent phase and decreases the risk of chronic complications of medication side-effects. 9 Given the lack of data using hormones for patients with rising PSA after RT, data from neoadjuvant trials must be reviewed.
Lawton and colleagues looked prospectively at RT with long-term adjuvant goserelin compared to RT with hormonal therapy added only at clinical relapse in patients with stage T3 prostate cancer. 10 They found an improved biochemical NED defined as a PSA 1.5 (8% vs 32%) at 8 y in patients who were given hormonal therapy earlier, but no statistical difference in cause specific failure or absolute survival. This effect on biochemical NED survival, and lack of effect on overall survival, was confirmed on subset analysis by Horowitz. 11 The UK's Medical Research Council did find an improvement in cancer specific survival for immediate as opposed to delayed hormonal treatment in patients without metastases, potentially analogous to PSA-only recurrence. 12 However, there are no randomized trials addressing the use of hormonal therapy as treatment in PSA-only progression, and long-term efficacy and survival benefit is unclear. 12 In addition, the side-effect profile of androgen therapy is significant, including a 100% rate of impotence as well as osteoporosis, anemia, altered lipid metabolism and personality changes. 9 Hormonal therapy post-operatively Messing and colleagues randomized post-prostatectomy patients with positive lymph nodes to immediate androgen blockade or observation until clinical progression. 13 They found an overall improved survival with early hormonal treatment of 80% vs 60%. While this seems to set a standard for pathological node positive patients, the question remains for patients with PSA levels rendered undetectable post-operatively who subsequently recur.
As stated above in the post-RT population, this is another area ripe for clinical trials. Prospective data should be generated using salvage (secondary?) hormonal therapy for biochemical failure.
Conclusions
Many variables in addition to PSA level are involved in the decision to commence salvage therapy for biochemical failure of prostate cancer. There will be an estimated 50 000 patients/y who will have a PSA-only recurrence. These data reveal a general lack of consensus and point to the need for further randomized trials and consensus conferences addressing treatment for biochemical-only recurrence.
Appendix: Questionnaire Please answer the following questions describing the point at which you would recommend radiation therapy for a patient with rising PSA after radical prostatectomy:
(1) For two patients with similar grade, T-and N-stage, performance status, post-operative latency, PSA velocity and ploidy, please mark your PSA cut-off: Table B5 (a) For a patient who is able to carry on normal daily functions? 0 1 2 3 4 5 10 Other Never (b) For a person unable to work, but to care for self with varying amount of assistance? 0 1 2 3 4 5 10 Other Never (c) For a person in institutional care requiring significant assistance? 0 1 2 3 4 5 10 Other Never (7) For two patients with similar age, grade, T-and N-stage, performance status, post-operative latency, and ploidy, please mark your PSA cut-off: 
